Biotechnology, crucial in addressing the global challenge posed by rare diseases 29/02/2024 Healthcare Rare diseases Biotechnology is providing answers to rare diseases in areas with unresolved clinical needs such as diagnosis and... AseBio
Biotechnology emerges as a key player in the fight against rare diseases 29/02/2024 In Spain, around three million people live with rare diseases or are in search of a diagnosis. Only 20% of the over 6... AseBio
ARTHEx Biotech Receives IND Clearance from FDA to Initiate the Phase I-IIa ArthemiR™ Tria... 28/02/2024 Healthcare Innovative drugs ATX-01 is the industry’s first microRNA therapeutic to be evaluated for DM1 and the first program from ARTHEX’s pipeline... Partners - ARTHEx Biotech
Vaxdyn leads the KLEBSIELLA project to work on the prevention of one of the most worrisome... 28/02/2024 Healthcare Antibiotic resistance Vaxdyn leads the KLEBSIELLA research project against the antibiotic-resistant bacterium Klebsiella pneumoniae, which... Partners - Vaxdyn
Why and how to involve rare disease patients in the evaluation process of a new health tec... 27/02/2024 Healthcare Rare diseases Innovative drugs Personalized medicine Advanced therapies Alira Health experts explain in an interview the importance of involving patients with rare diseases in the evaluation... Partners
ORYZON reports financial results and corporate update for quarter ended December 31, 2023 27/02/2024 Healthcare Innovative drugs Personalized medicine Advanced therapies Oryzon Genomics, a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with... Partners - Oryzon Genomics
INNOVATIVE THERAPIES DAYS Francia Del 10/10/2024 to 11/10/2024 Healthcare Advanced therapies International
BCN HEALTH publishes a study evaluating hospital incidence and medical costs associated wi... 26/02/2024 Healthcare Rare diseases BCN HEALTH has published the study "Incidence and medical costs of lupus in Spanish hospitals: a retrospective database... Partners - BCN Health
AMSbiopharma introduces an important advance for the analysis of nitrosamines in different... 23/02/2024 Healthcare Drug discovery Nitrosamines represent a significant health risk, being potentially carcinogenic and a major concern in pharmaceutical... Partners - AMSbiopharma
Almirall licenses an anti-IL-21 monoclonal antibody from Novo Nordisk to develop it as a f... 22/02/2024 Healthcare Access to innovation Drug discovery Innovative drugs NN-8828 is a first-in-class monoclonal antibody in dermatology with high affinity for the cytokine IL-21 that has been... Partners - Almirall
